| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $779,626 | 3 | 33 |
Sells | $2,653,181 | 6 | 67 |
| RA CAPITAL MANAGEMENT, L.P. | 3 | $779,626 | 0 | $0 | $779,626 | |
| Brennan Aoife | President and CEO | 0 | $0 | 1 | $406,979 | $-406,979 |
| Thomas Stephen Basil | director | 0 | $0 | 5 | $2.25M | $-2.25M |
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem …
Over the last 12 months, insiders at Climb Bio, Inc. have bought $779,626 and sold $2.65M worth of Climb Bio, Inc. stock.
On average, over the past 5 years, insiders at Climb Bio, Inc. have bought $779,626 and sold $1.34M worth of stock each year.
Highest buying activity among insiders over the last 12 months: RA CAPITAL MANAGEMENT, L.P. () — $779,626.
The last purchase of 7,111 shares for transaction amount of $24,889 was made by RA CAPITAL MANAGEMENT, L.P. () on 2026‑01‑05.
| 2026-09-15 | Sale | Thomas Stephen Basil | director | 100,000 0.1716% | $13.67 | $1.37M | -21.93% | |
| 2026-06-29 | Sale | Brennan Aoife | President and CEO | 30,902 0.0447% | $13.17 | $406,979 | -3.44% | |
| 2026-02-26 | Sale | Thomas Stephen Basil | director | 16,313 0.0227% | $7.01 | $114,289 | +51.35% | |
| 2026-02-25 | Sale | Thomas Stephen Basil | director | 33,687 0.0488% | $7.00 | $235,964 | +57.33% | |
| 2026-02-13 | Sale | Thomas Stephen Basil | director | 10,000 0.015% | $5.81 | $58,141 | +94.89% | |
| 2026-02-12 | Sale | Thomas Stephen Basil | director | 90,000 0.1311% | $5.23 | $470,988 | +109.20% | |
| 2026-01-05 | RA CAPITAL MANAGEMENT, L.P. | 7,111 0.009% | $3.50 | $24,889 | +205.08% | |||
| 2025-12-12 | RA CAPITAL MANAGEMENT, L.P. | 101,462 0.1055% | $2.86 | $290,181 | +250.67% | |||
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. | 213,099 0.1689% | $2.18 | $464,556 | +355.65% | |||
| 2025-06-30 | Sale | Brennan Aoife | President and CEO | 20,618 0.0091% | $1.22 | $25,154 | +238.71% | |
| 2025-06-20 | Sale | Pimblett Emily | SVP, Finance & CAO | 1,242 0.0006% | $1.24 | $1,540 | +213.22% | |
| 2025-03-20 | Sale | Pimblett Emily | SVP, Finance & CAO | 1,199 0.0006% | $1.31 | $1,571 | +48.44% | |
| 2024-12-19 | Sale | Pimblett Emily | CHIEF ACCOUNTING OFFICER | 1,235 0.0009% | $2.02 | $2,495 | -14.62% |
| Increased Positions | 38 | +43.18% | 11M | +25.08% |
| Decreased Positions | 41 | -46.59% | 25M | -55.34% |
| New Positions | 17 | New | 6M | New |
| Sold Out Positions | 19 | Sold Out | 3M | Sold Out |
| Total Postitions | 85 | -3.41% | 31M | -30.26% |